NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I agree, but it depends on the holdup. If it is a reviewer that does not want to be officially ahead of the agency, or it could be that only UK guidance matters and in fact the UK is ahead of the FDA. So I agree, at this point, especially after the recent journal article, it may not matter. To some degree I have decided that is likely, but can’t say for certain. I do think that was a real reason for a delay.